Statement: There was over 10% more cases of adverse events in cohort 2 than in cohort 1 of the primary trial.
Primary_evidence: Adverse Events 1:   Total: 2/15 (13.33%)   Sinus Tachycardia * 0/15 (0.00%)   Acute coronary syndrome * 0/15 (0.00%)   Obstruction Gastric * 0/15 (0.00%)   Vomiting * 0/15 (0.00%)   Hemorrhoids * 0/15 (0.00%)   Nausea * 0/15 (0.00%)   Duodenal ulcer * 0/15 (0.00%)   Hepatic pain * 0/15 (0.00%)   Infections and infestations-other *  [1]0/15 (0.00%)   Lipase Increased * 0/15 (0.00%) Adverse Events 2:   Total: 11/35 (31.43%)   Sinus Tachycardia * 1/35 (2.86%)   Acute coronary syndrome * 1/35 (2.86%)   Obstruction Gastric * 1/35 (2.86%)   Vomiting * 3/35 (8.57%)   Hemorrhoids * 1/35 (2.86%)   Nausea * 3/35 (8.57%)   Duodenal ulcer * 1/35 (2.86%)   Hepatic pain * 1/35 (2.86%)   Infections and infestations-other *  [1]1/35 (2.86%)   Lipase Increased * 1/35 (2.86%)